Category Archives: Transhuman News

The days of cream and sugar are over. There's a new ingredient in town that everyone is putting in their coffeeand it's not just for flavor: adaptogens.

"Adaptogens are nontoxic herbal pharmaceuticals which claim to help us better cope with (or increase our resistance to) mental or physical stress, improving physical and mental performance, and possibly supporting the immune system," says Silvia Carli, MS, RD, registered dietitian for 1AND1 LIFE. (Related: 11 Healthy Foods That Make You Smarter, According to Doctors.)

Many of the new canned and bottled coffee drinks use adaptogens to help deliver all the focus of caffeinated coffee but with less of a crash or jitters while providing stress-relieving benefits.

While adaptogens have been used for thousands of years in traditional herbal medicine, they're only recently becoming more commonplace as more research is being done to confirm their benefits.

"Functional mushrooms are finally having their moment in the public spotlight, in large part due to the growing amount of research into their health benefits as well as their applications in food," says Kerry Hughes, MS, CNC, a certified clinical nutritionist, ethnobotanist and herbalist who is on the Scientific Advisory Board for Good Pharma.

If you've ever felt too jittery after drinking plain coffee, you might be interested in drinking adaptogen-enriched coffee, which is often much lower in caffeine than a traditional cup of joe while also having the benefits of functional mushrooms.

As adaptogens have been linked to lower stress levels, adding them to coffee may help to lower our level of stress and burnout in an easy wayby adding it to something we drink every day anyway.

"The search is on for more natural and accessible ways to manage stress that may also have additional health benefits such as increased cognitive function as well as boost immunity," says Aimee Plauche, RD, an advising registered dietitian for ICONIC. And adaptogens are one of the ways to do this.

These mushrooms and roots have been used in Chinese and Ayurvedic medicine for thousands of years, but we're just starting to do more research into adaptogens to prove their benefits.

"While more research is needed, studies on the utility of certain adaptogens seem promising," saysKylie Ivanir, MS, RD, a registered dietitian atWithin Nutrition.

"Studies conducted in animals and in human cell samples have shown that adaptogens may indeed demonstrate neuroprotective activity, have anti-fatigue and antidepressant properties, and can serve as a stimulant for the central nervous system. Studies have shown that particular adaptogens, such as Rhodiola extract, can improve cognitive function and combat fatigue," says Ivanir.

She adds that larger research studies completed on humans are needed to determine the efficacy of each particular adaptogen.

There are a few common adaptogens that are used more frequently in coffee:

Adaptogen coffee has some great added benefits, but experts say you shouldn't be drinking it as a solution to your underlying health problems.

"It's not that adaptogens would not improve your quality of life if you are extremely stressed, but is that the factor that is going to make the biggest difference?" says Carli.

She recommends taking a closer look at your daily habits: "I want to invite the readers to reflect on a couple of points: are there other adjustments that we can make in our daily routine to ease the stress in our lives? For example: are we practicing self-care, eating an overall healthy, varied, and balanced diet without overly processed foods? Are we sleeping well? Do you journal? Do you exercise? Do you have an outlet to talk about your stressors?" says Carli.

If you're dealing with a lot of stress, it might be best to combine your adaptogen coffee with other stress-reducing habits.

Adaptogens aren't for everyone. And it's not just about personal preferencetaking adaptogens isn't safe for certain people.

"It is important to note that certain adaptogens may not be safe for everyone including pregnant women, so it is always best to consult with your healthcare provider," says Ivanir.

As with any supplement, Carli notes that you should make sure the adaptogens you're consuming are safeespecially considering that these are a fairly new product.

"When new supplements get on the market quickly due to new trends (sometimes poorly supported by research), the process of testing for quality and purity is not always ideal and thorough, which means that we are not certain of the actual contents of that supplement and it could turn out being harmful to health," says Carli. (Related: 6 Popular Supplements That Don't Actually Work, According to Experts.)

That's why Ivanir tells that it's important to choose reputable brands that have been third-party tested to ensure there are no contaminants or heavy metals.

And although the benefits of adaptogens sound enticing, it's always good to keep in mind that it's best to not rely on taking these ingredients alone for their benefits without following a well-balanced diet.

"Adaptogens should not take the place of a balanced diet, physical activity, and any necessary medications, they may be used as a supplement to support overall health," adds Ivanir.

So in addition to drinking adaptogen coffee, you can also try these22 Proven Tricks That Melt Stress.

For more healthy eating news, make sure to sign up for our newsletter!

Read more here:
The One Ingredient Everyone's Adding to Their Coffee | Eat This Not That - Eat This, Not That

March 19, 2021 @ 13:28 by Chloe Holmes

Together with VOICE, The UKs National Innovation Centre for Ageing will launch their very first citizen-led community in the US.

Through a commercial agreement, VOICE (Valuing Our Intellectual Capital & Experience) and the UKs National Innovation Centre for Ageing (NICA) have set up a partnership with a non-profit organisation called amazing.community.

Headquartered in New Jersey (US) the amazing.community supports women aged 45+ as they navigate the present and future of work in this digital world; the organisation offers cutting edge skills building opportunities, curated resources, and an open virtual door for women 45+ to connect meaningfully with each other.

This new partnership will help build a more diverse VOICE community and facilitate cultural exchanges between US and UK. NICA and amazing.community will work together to explore the impact of technology at work, ageism, gender equality, cultural differences and the many issues and challenges that need to be addressed to ensure women over 45 thrive in the workplace now and in the future.

All this is building a deep global knowledge and rich consumer insights on healthy ageing. It gives businesses, entrepreneurs, innovators, and policy makers a novel and unique source of data and insights, building the evidence base to rapidly inform the development of new products and services helping people to live well for longer and tapping into a billion-pound longevity economy.

NICA, who are based within Newcastle University, UK on Newcastle Helix, is the UK home of Ageing Intelligence, which brings together data driven insight and human experiences to help bring new products, business models and services to market. VOICE is part of NICA and leads dialogue with citizens on what is needed for healthy ageing.

VOICE currently has a citizen network of more than 8,000 people the UK and this expansion is part of NICAs strategy to provide services and insight on ageing at a global level. It is intended that this business model will be replicated in other countries around the world, building a broader repository of data and insight to empower new business opportunities and ideas.

Professor Lynne Corner, chief operating officer at NICA and director of VOICE said: This marks the first step in our global ambitions for the VOICE community and we are thrilled to partner with the wonderful team at amazing.community and support ageing innovation in the US.

This is a strategic decision to develop a more culturally and gender diverse community to generate broader, deeper, richer insights and cultural exchanges between individuals from all over the world. It will provide to clients, business and policy makers a novel and unique source of insight.

This new business model is not only commercially viable, but also a way to empower parallel communities to come together and amplify their voices sharing experiences, exchanging insights, and building on common ground. Our plans will not only support international longevity economies but make a lasting impact on peoples lives helping them live well for longer.

amazing.community will be able to take advantage of ten years of operational expertise in community engagement from the VOICE network in the UK. Branded as Amplified by VOICE, amazing.community has customized the VOICE digital platform to engage and grow their existing community as well as to invite more robust collaboration with companies, non-profits and other organisations.

Dr. Ashley Ater Kranov, executive director of amazing.community, said: Im thrilled to announce our global partnership with VOICE. It has been nearly a year in the making and we are beyond ready to bring our communities together.

This partnership forwards one of our strategic initiatives: to establish close ties with a center for aging known for applied research, community engagement, and a commitment to transforming individual lives and impacting policy. Our collaboration will allow each of our communities to participate in tech skills building opportunities, quality of life research studies and special interest group discussions offered by both organizations.We believe doubling our offerings and opening the door to an international community will meaningfully enhance our efforts to expand the work horizon for women 45+ who are looking to re-enter the workforce, pivot to a new career or start their own businesses.

To celebrate this global partnership, and to bring both communities together for an engaging cross Atlantic conversation, they will watch the exclusive premiere of the film Les Dames (Ladies).

The acclaimed Swiss film Ladies by directors Stphanie Chuat, Vronique Reymond is a movie that reveals the passions, intimacy, and desires of five women who, at the dawn of their 60s or older, dream of their future. This will be a first-world premiere and will also mark the start of a joint research piece on love, life, companionship for women in later life.

For more information or to sign up to be part of the VOICE community visit https://www.voice-global.org/about/ (UK) or https://amazing.community (US).

Here is the original post:
Global expansion for UK National Innovation Centre with a new VOICE in the US - North East Times

EDISON BIO is expanding human health potential.

HOUSTON (PRWEB) March 19, 2021

Houston health tech company EDISON BIO has launched what may be the most comprehensive executive health exam on the planet. This new physical of the future aggregates a wide array of health data to create a truly universal digitalization of patients minds and bodies focused on improving longevity and performance. EDISON BIOs Artificial Intelligence, combined with a team of medical experts, analyzes health changes at the first signs of detection long before they have the chance to progress into serious health concerns. By analyzing this personalized data, EDISON BIO can uncover potential health risks and create an educational, highly personalized health strategy focused on optimizing diet, exercise, and lifestyle to improve overall performance and longevity. This approach aims to empower people to achieve the most in-depth understanding of all areas of their health in a way never before imagined.

Despite all the advances of modern medicine, todays healthcare system still largely takes a reactionary approach, catching disease only after symptoms manifest. By that time, it is often too late to reverse the resulting damage. The team at EDISON BIO believes that no one should have to wait until their disease becomes too harmful for treatment and is accelerating access to the latest in medical detection technology.

In contrast to the routine exam and minimal blood work done by many doctors today, EDISON BIO uses the latest technology to collect extensive data including full-body MRI imaging, a full array of genomic technology including whole genome sequencing, extensive blood analysis, and diet, lifestyle, and mental health evaluations to determine current and future health risks. This scientifically quantified data empowers members with confidence and peace of mind as to the comprehensive state of their health.

EDISON BIOs founder realized the need for proactive awareness of health risks when a cancer screening technology saved his mothers life. Around the same time, a family friend passed away after cancer was detected too late. He and his team have spent nearly twenty years researching and experimenting with medical technology to make medicine more personalized and less reactionary in nature. He believes that it will change the way people engage with their health through anticipating concerns early on and empowering people with personalized tools to achieve their optimum health.

EDISON BIO conducts exams at their members preferred location, including their homes, corporate offices, or wherever they are requested. After the biomarkers are analyzed, they offer an easy-to-understand educational plan to address concerns as well as rapid access to the worlds leading experts if a rare condition or disease is detected.

EDISON BIO is using evidence-based, data-driven technology to expand human health potential. Named in homage to Thomas Edisons invention of the light bulb, EDISON BIO is illuminating the future of healthcare in the twenty-first century by providing a more personalized, preventive, and data-driven approach to health.

EDISON BIO Contact: http://www.edisonbio.com / support@edisonbio.com / Phone: 888-366-0123

Share article on social media or email:

See original here:
EDISON BIO Launches Advanced Executive Health Exam For Early Detection Of Health Risks - PR Web

Light and heat sensors on a building at the University of Southern Denmark adjust shutters to optimize indoor conditions.

The Smart City Index (1) defines a smart city as an urban setting that applies technology to enhance the benefits and diminish the shortcomings of urbanization for its citizens. The top-ranked city, Singapore, has addressed urban challenges with information technology since 2014 through its Smart Nation Initiative (2). The influence of technology is reflected in the city's open platform for sharing energy data, crowd-sourced location data for smart navigation, and even online forums for citizen participation in policy-making (2). The smart city concept requires the acquisition of massive amounts of data in real time, and large networks of smart devices must spread the burden of communication and processing evenly across the network to prevent information overload at its center. Opportunities to solve this challenge have recently emerged through the development of increasingly smart materials that can sense, process, and respond to environmental stimuli without centralized resources.

A recent market analysis predicted that the number of connected devices, sensors, and actuators that constitute the Internet of Things (IoT) will reach more than 46 billion in 2021, driven largely by reduction in hardware costs to as little as $1 per device (3). Inexpensive connected sensing devices measuring strain, temperature, and humidity (4), as well as the enhancement of indirect sensing methods that use computer vision and crowd-sourcing (5), provide vast amounts of data to quantify the built environment (6). The ability to continuously monitor the physical state of infrastructure with high resolution in time and space has exciting implications for sustainability and equity. Quantitative, data-driven decision-making can enable predictive maintenance in place of conventional intuition-based workflow, although such automated systems can also learn to replicate human biases (7).

However, efficient decision-making based on these data streams becomes limited by the burden of transmitting and processing the raw, unprioritized data. As the number of connected devices rises, smart cities have shifted from a hierarchical network architecture based on cloud computing to a more decentralized information ecosystem. In this so-called fog computing model, data processing is performed at the edge of the network to avoid costly communication with a central cloud server (8). Alternatively, mist computing represents an even more extreme paradigm in which data processing is handled by microprocessors attached directly to the sensors and actuators. One advantage of mist computing is a reduced burden on communications systems by constraining information to a need-to-know basis. This approach has an added sustainability benefit because communication among IoT devices accounts for as much as five times the power consumption necessary for the computation itself (9).

Infrastructure decision-making can benefit from distributed sensor data if data can be processed efficiently. Data management can benefit from need-to-know processing strategies, as illustrated for the construction of a subway system, where tunneling can create ground-surface subsidence that can undermine an overlying building. At the city scale, analysis of these data can lead to decisions to mitigate subsidence impact, such as stopping tunneling or adding underlying support.

Orthogonal to these advances in IoT technology, multifunctional and responsive materials have been designed to substantially alter their shape or properties in response to external stimuli. When taken to the extreme, this concept results in living materials, which use biological organisms (10) as highly efficient chemical machines for sensing and responding to their environment. Such materials are engineered to sense and regulate their state at the microscopic scale to effect macroscopic structural or functional changes. A common function of smart or living materials is self-healing to improve the service life of a larger structure in support of its sustainability. For example, bacteria-triggered self-healing represents one of the most popularized concepts in living cementitious materials. Extensive research has been conducted on the use of extremophiles and engineered bacteria to imbue materials with the self-sensing capacity needed to trigger these self-healing properties (10).

In effect, these smart and living materials participate in an extreme version of the mist-computing model for structural health monitoring. Chemical gradients in the cement are detected, interpreted, and acted upon by means of incredibly low-power sensing and response mechanisms without increasing the communication and processing burden on the built environment. This latter point is critical because the electronic sensing and transmission of millimeter-scale chemical gradients across an entire smart city would absolutely overwhelm digital data processing systems. Information at this small scale is also irrelevant to decisions being made for an entire city block, so restricting it to an appropriate level reduces the cognitive load on stakeholders such as building managers and government policymakers (see the figure). This approach is analogous to how the human nervous system coordinates the contraction of many millions of cells through a hierarchy of control structures, rather than by consciously addressing individual muscle fibers.

Smart materials can also process data without the assistance of active biological matter. A fascinating example of computation in material substrates is the recent demonstration of photonic metamaterials (internally structured materials) that can solve complex mathematical equations (11). These devices exploit diffractive optics to leverage material microstructure into passive, all-optical transformations. A complementary idea is that of mechanologic, in which a mechanical metamaterial deforms in a preprogrammed way to combine computation and actuation (12). Given the rapid advancements in design and fabrication of these extraordinary materials, a next generation of smart materials may emerge with programmed thermal, optical, and mechanical responses acting as a self-sensing, self-actuating smart faade, or as a solar tracker to improve the efficiency of photovoltaic energy harvesting (13).

With connected sensors being deployed to provide real-time structural health monitoring of critical infrastructure [e.g., bridges, dams, residential and commercial buildings, and even temporary structures (14)], managing the flood of data is more important than ever to prevent smart cities from suffering analysis paralysis. Smart and living materials may push data processing to previously unimagined extremes, with the literal foundations of the built environment acting as analog-computing substrates. This approach should offer pronounced advantages for sustainability, including increased longevity of infrastructure, reduced waste from the proliferation of electronic sensors, and reduced power consumption from communications. Moreover, the current challenge to implementation of mist-computing infrastructures is tied to their complexity and size, which are too great to manage by centralized systems (15). Thus, autonomous smart materials present a compelling tool in achieving robust and sustainable structural health monitoring in smart cities of the future.

Acknowledgments: We thank Z. Ounaies for inspiring our research collaborations.

See the original post here:
Smart cities built with smart materials - Science

New York, March 16, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Stem Cell Therapy Industry" - https://www.reportlinker.com/p06033005/?utm_source=GNW In addition to being a global intelligence exchange platform, MarketGlass is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack. - Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations.

Abstract: - Global Stem Cell Therapy Market to Reach $242.3 Million by 2027 - Amid the COVID-19 crisis, the global market for Stem Cell Therapy estimated at US$127.5 Million in the year 2020, is projected to reach a revised size of US$242.3 Million by 2027, growing at aCAGR of 9.6% over the period 2020-2027. Allogeneic, one of the segments analyzed in the report, is projected to record 9.9% CAGR and reach US$228.6 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Autologous segment is readjusted to a revised 5.6% CAGR for the next 7-year period. - The U.S. Market is Estimated at $37.8 Million, While China is Forecast to Grow at 9% CAGR - The Stem Cell Therapy market in the U.S. is estimated at US$37.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$41.9 Million by the year 2027 trailing a CAGR of 9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.8% and 7.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.8% CAGR.

Select Competitors (Total 33 Featured) -

Read the full report: https://www.reportlinker.com/p06033005/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession Global Competitor Market Shares Stem Cell Therapy Competitor Market Share Scenario Worldwide: ( in %): 2020E Global Competitor Market Shares by Segment

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Allogeneic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Allogeneic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Allogeneic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Autologous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Gastrointestinal Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Gastrointestinal Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Gastrointestinal Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Musculoskeletal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Musculoskeletal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Musculoskeletal Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Wounds & Injuries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Wounds & Injuries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Wounds & Injuries by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Adipose Tissue-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Adipose Tissue-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Adipose Tissue-Derived MSCs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Bone Marrow-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 29: World Historic Review for Bone Marrow-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 30: World 15-Year Perspective for Bone Marrow-Derived MSCs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 31: World Current & Future Analysis for Cord Blood / Embryonic Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 32: World Historic Review for Cord Blood / Embryonic Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 33: World 15-Year Perspective for Cord Blood / Embryonic Stem Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 34: World Current & Future Analysis for Other Cell Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 35: World Historic Review for Other Cell Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 36: World 15-Year Perspective for Other Cell Sources by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES Market Facts & Figures Market Analytics Table 37: USA Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 38: USA Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 39: USA 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 40: USA Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 41: USA Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 42: USA 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

Table 43: USA Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 44: USA Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 45: USA 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027

CANADA Table 46: Canada Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 47: Canada Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 48: Canada 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 49: Canada Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 50: Canada Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 51: Canada 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

Table 52: Canada Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 53: Canada Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 54: Canada 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027

JAPAN Table 55: Japan Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 56: Japan Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 57: Japan 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 58: Japan Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 59: Japan Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 60: Japan 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

Table 61: Japan Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 62: Japan Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 63: Japan 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027

CHINA Table 64: China Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 65: China Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 66: China 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 67: China Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 68: China Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 69: China 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

Table 70: China Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 71: China Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 72: China 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027

EUROPE Market Facts & Figures Market Analytics Table 73: Europe Current & Future Analysis for Stem Cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 74: Europe Historic Review for Stem Cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 75: Europe 15-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027

Table 76: Europe Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 77: Europe Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 78: Europe 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 79: Europe Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 80: Europe Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 81: Europe 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

Table 82: Europe Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 83: Europe Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 84: Europe 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027

FRANCE Table 85: France Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 86: France Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 87: France 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 88: France Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 89: France Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 90: France 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

See the article here:
Global Stem Cell Therapy Market to Reach $242.3 Million by 2027 - GlobeNewswire